Assessment of the Interest of the Atalante Device for Patients With Manual Wheelchairs
NCT ID: NCT05909774
Last Updated: 2023-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2016-12-09
2017-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A motorized mechanical exoskeleton is an external device intended to compensate for a muscular or neurological deficiency enabling paraplegics to stand and walk again. The Atalante exoskeleton, designed by Wandercraft company allows patients to stand upright and walk without the aid of crutches.
This early study was the first clinical investigation of the Atalante exoskeleton performed early in the development. It was used to evaluate the device design concept with respect to initial clinical safety and device functionality and guided further device modifications.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of the Atalante Exoskeleton on Standing and Walking in Individuals With Paraplegia: A Prospective Controlled-Environment Study in a Rehabilitation Context
NCT06941896
Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis
NCT04110561
Evaluation of Usability and Safety of the System Atalante in Patients With High Paraplegia and Tetraplegia
NCT06939634
Multitissular Effect of Vertical Mobilization Using the Exoskeleton AtalanteTM in Neurological Chair- or Bed-bound Patients
NCT05506306
Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis
NCT06199284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this multi-centric clinical trial, patients were asked to perform between 1 and 2 days of training with Atalante exoskeleton including device training and evaluations (up to 9 hours of training and 3 hours of evaluation per patient).
The primary objective of this study was to assess patients' ability to walk straight- for 10 meters with the Atalante exoskeleton during 10-meters walk test (10MWT).
Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.
The secondary objectives focused on performance evaluation with the Atalante exoskeleton. The assessments performed were:
1. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid walking assistance used by the patient on the walking, verticalization (or sit-to-stand), static and dynamic balance ability
2. Assessment of the static and dynamic postural stability of the subject with the Atalante exoskeleton by observation of center of pressure displacement and velocity
3. Assessment of the perceived effort by the patient
4. Assessment of perceived safety by the patient
5. Assessment of the overall satisfaction of patients after using the exoskeleton
6. Comparison of the two types of walk on walking ability, perceived effort, and safety
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exoskeleton second
This group first perform tests without Atalante exoskeleton and secondly with Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the "Continuous" walk and then with the "Push \& Swing" walk, and the other half doing the opposite.
Test with Atalante exoskeleton in "continuous walk" type
The "continuous" walk is smoother and more physiologic than the "push and swing" walk
Exoskeleton first
This group first perform tests with Atalante exoskeleton and secondly without Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the "Continuous" walk and then with the "Push \& Swing" walk, and the other half doing the opposite.
Test with Atalante exoskeleton in "continuous walk" type
The "continuous" walk is smoother and more physiologic than the "push and swing" walk
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test with Atalante exoskeleton in "continuous walk" type
The "continuous" walk is smoother and more physiologic than the "push and swing" walk
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Daily and autonomous use of wheelchair
* Paraplegia with level of injury between T6 and S1
* Patient unable to walk, neither during physiotherapy session nor in a daily routine
* Patient with cognitive capacities: able to understand oral and/or written instructions, as well as instructions given by demonstration
* Able to use their upper limbs
* Can be verticalized
* Patient with a health care insurance
* Patient having given his/her written consent
* Joints amplitudes compatible with the use of the exoskeleton:
* Hip: Flexion\>115°; Extension\>15°; Abduction\>17°; Adduction \>10°; Medial rotation\>35°; Internal rotation\>10°
* Knee: Flexion\>105°; Extension\> -5°
* Ankle: Flexion\>0°; Extension\>9°; Supination\>18°; Pronation\>18°
Exclusion Criteria
* Bad control of the trunk
* Vestibular disorder (loss of balance, dizziness, …) when placed in the vertical position
* Upper limbs involuntary shivers and/or movements
* Pregnant women
* A lower or upper limb amputated
* Epilepsy
* Patient carrying an active implantable medical device
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wandercraft
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thierry Albert, MD
Role: PRINCIPAL_INVESTIGATOR
COS CMPR de Bobigny
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CEREMH (Centre de ressources et d'innovation mobilité handicap)
Vélizy-Villacoublay, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A01257-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.